A National Study of HPV Vaccination of Adolescent Girls: Rates, Predictors, and Reasons for Non-Vaccination
- 2.4k Downloads
Despite recommendations in the U.S. for routine HPV vaccination of adolescent girls since 2006, rates of vaccination continue to be low. This study reports vaccination uptake, factors associated with vaccine uptake and reasons for non-vaccination within a national sample of adolescent females during 2010. Using a computer administered survey of a national sample of 501 mothers of daughters 14–17 years old we assessed maternal reports of HPV vaccination as well as socio-demographical factors, maternal HPV exposures and reasons chosen for non-vaccination. Reported HPV vaccination rates were slightly over 50 % (51.1 %), with 38.3 % reporting completion of all 3 doses. Socioeconomic and demographic factors were not associated with vaccination initiation; however, Blacks and Hispanics were less likely to complete vaccination. The most common reasons for non-vaccination were concerns about vaccine safety, danger to daughter, and provider non-recommendation. Relatively poor HPV vaccine initiation and only modest 3-dose completion continues to be a major public health concern that requires continued efforts to address identified predictors and reasons for non-vaccination.
KeywordsHPV Vaccination rates Adolescent health behaviors Sexually transmitted infections
Funding support for this research was provided by NIH R56 A1079090-01A1.
Conflict of interest
Kester, Laura: Has no financial disclosures. Zimet, Gregory: Investigator on grants funded through Merck’s Investigator Initiated Studies Program. In the past year served as a consultant to Sanofi Pasteur regarding attitudes about herpes vaccination. Shew, Marcia: Investigator for Merck and Co. related HPV vaccine trials. Kahn, Jessica: Co-PI of two clinical trials of HPV vaccine in HIV-infected individuals; vaccine and immunogenicity testing were provided by Merck. Fortenberry, J Dennis: Receives compensation from American Social Health Association for continuing lectures related to HPV vaccines.
- 1.Morbidity and Mortality Weekly Report (MMWR). (2007). Quadrivalent human papillomavirus vaccine. CDC, 56(RR02), 1–24. www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm.
- 2.Morbidity and Mortality Weekly Report (MMWR). (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). CDC, 59(20), 626–629. www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm.
- 3.Morbidity and Mortality Weekly Report (MMWR). (2007). QuickStats: Prevalence of HPV infection among sexually active females aged 14–59 years by age group. National Health and Nutrition Examination Survey, United States 2003–2004. CDC. www.cdc.gov/mmwr/preview/mmwrhtml/mm5633a5.htm.
- 5.Morbidity and Mortality Weekly Report (MMWR). (2010). National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2009. CDC, 59(32):1018–1023. www.cdc.gov/mmwr/preview/mmwrhtml/mm5932a3.htm?s_cid=mm5932a3_e%0d%0a.
- 6.Morbidity and Mortality Weekly Report (MMWR). (2011). National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. CDC, 60(33). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6033a1.htm.
- 21.Society, A. C. (2010). Cancer facts and figures 2010. Alanta: American Cancer Society.Google Scholar
- 22.Bingham, A., Drake, J. K., & LaMontagne, D. S. (2009). Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Archives of Pediatrics & Adolescent Medicine, 163(5), 455–461.Google Scholar